ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
20.340,57
0,65%
S&P 500
5.934,09
-0,69%
Dow Jones
42.663,64
-0,10%
Euro vs US Dollar
1,03592
-0,23%
Bitcoin
96.674,35
-5,49%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Exelixis Inc (EXEL)

  7. Exelixis Inc (EXEL) News

EXEL

Exelixis (EXEL)

Exelixis Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:EXEL
DatumZeitQuelleÜberschriftSymbolFirma
06/01/202522h05Business WireExelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025NASDAQ:EXELExelixis Inc
24/12/202402h16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EXELExelixis Inc
03/12/202402h29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EXELExelixis Inc
29/11/202419h12Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EXELExelixis Inc
27/11/202422h05Business WireExelixis to Webcast Fireside Chats as Part of Investor Conferences in DecemberNASDAQ:EXELExelixis Inc
27/11/202401h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EXELExelixis Inc
26/11/202422h05Business WireExelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine TumorsNASDAQ:EXELExelixis Inc
22/11/202422h01Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EXELExelixis Inc
20/11/202402h03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EXELExelixis Inc
20/11/202402h03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EXELExelixis Inc
20/11/202402h03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EXELExelixis Inc
20/11/202402h03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EXELExelixis Inc
20/11/202402h02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EXELExelixis Inc
20/11/202402h02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EXELExelixis Inc
19/11/202400h50Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EXELExelixis Inc
18/11/202422h10Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EXELExelixis Inc
08/11/202401h44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EXELExelixis Inc
07/11/202422h05Business WireExelixis to Webcast Fireside Chats as Part of Investor Conferences in NovemberNASDAQ:EXELExelixis Inc
06/11/202401h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EXELExelixis Inc
06/11/202401h04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EXELExelixis Inc
05/11/202422h23Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EXELExelixis Inc
01/11/202423h44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EXELExelixis Inc
01/11/202423h43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EXELExelixis Inc
01/11/202421h54Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EXELExelixis Inc
01/11/202421h47Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EXELExelixis Inc
30/10/202423h04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EXELExelixis Inc
30/10/202421h10Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EXELExelixis Inc
29/10/202421h11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EXELExelixis Inc
29/10/202421h07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EXELExelixis Inc
29/10/202421h05Business WireExelixis Announces Third Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:EXELExelixis Inc
 Showing the most relevant articles for your search:NASDAQ:EXEL

Kürzlich von Ihnen besucht

COIN
AVAXUSD
Avalanche
NYSE
DIS
Walt Disney
NASDAQ
QQQ
Invesco QQQ Trust Series 1
TG
MBG
MercedesBenz
PM
XAUUSD
Gold vs US Dollar
COIN
ETHUSD
Ethereum
TG
TUI1
Tui
NASDAQ
AMZN
Amazon.com
DBI
MDAX
MDAX
AMEX
XLE
Energy Select Sector SPDR
TG
DBK
Deutsche Bank
USOTC
BASFY
BASF (QX)
TG
RHM
Rheinmetall
AMEX
XLF
Financial Select Sector
CCOM
US30
US 30
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten